FDA Releases New Digital Template for Clinical Trials
Published Date: 5/22/2026
Notice
Summary
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final International Digital Protocol Standard
If you run or work at a company or research group that sponsors clinical trials, the FDA issued the final M11 CeSHarP guidance on May 22, 2026. It includes three documents (a guidance, a standardized template, and a technical specification) that set a harmonized format and data fields to share clinical trial protocol information electronically and was endorsed by the ICH Assembly in November 2025.
Guidance Is Voluntary, Not Binding
The M11 CeSHarP guidance reflects the FDA's current thinking and does not create legally enforceable duties. You may use a different approach if it still meets the applicable laws and regulations.
No New Paperwork Burden Under PRA
The guidance contains no new collection of information under the Paperwork Reduction Act and refers to existing clinical trial information collections in 21 CFR part 312 that are approved under OMB control number 0910-0014.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
2026-10188 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program
The FDA is updating how it collects info about drug making to keep medicines safe and high-quality. This affects drug makers who must follow good manufacturing rules and may see some changes in paperwork. Comments on these updates are open until June 22, 2026, so industry folks have time to weigh in before any new rules kick in.
Previous / Next Documents
Previous: 2026-10294 — Notice of Request for Revision to and Extension of an Information Collection; Standards for Privately Owned Quarantine Facilities for Ruminants
The USDA wants to update and keep collecting info from privately owned quarantine facilities that care for ruminants like cows and deer. This affects facility owners who must follow new rules to keep animals safe and healthy. Comments on these changes are open until July 21, 2026, and the update helps protect animals without adding big costs.
Next: 2026-10296 — Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is asking the public and businesses to share their thoughts on how it collects information to make sure it’s useful and not too much work. They want to cut down on paperwork, especially for small businesses with fewer than 25 employees. If you want to comment, you’ve got until July 21, 2026, so don’t miss your chance to help shape smarter rules!